- Home
- KMI vs CADL Comparison
KMI vs CADL Comparison
Compare KMI & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- CADL
- Stock Information
- Founded
- KMI 1936
- CADL 1999
- Country
- KMI United States
- CADL United States
- Employees
- KMI N/A
- CADL N/A
- Industry
- KMI Natural Gas Distribution
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- CADL Health Care
- Exchange
- KMI Nasdaq
- CADL Nasdaq
- Market Cap
- KMI 59.2B
- CADL 313.5M
- IPO Year
- KMI 2011
- CADL 2021
- Fundamental
- Price
- KMI $27.68
- CADL $4.94
- Analyst Decision
- KMI Buy
- CADL Strong Buy
- Analyst Count
- KMI 14
- CADL 5
- Target Price
- KMI $29.86
- CADL $19.80
- AVG Volume (30 Days)
- KMI 11.5M
- CADL 697.6K
- Earning Date
- KMI 10-15-2025
- CADL 11-13-2025
- Dividend Yield
- KMI 4.23%
- CADL N/A
- EPS Growth
- KMI 11.35
- CADL N/A
- EPS
- KMI 1.22
- CADL N/A
- Revenue
- KMI $15,969,000,000.00
- CADL N/A
- Revenue This Year
- KMI $11.25
- CADL N/A
- Revenue Next Year
- KMI $5.46
- CADL N/A
- P/E Ratio
- KMI $22.71
- CADL N/A
- Revenue Growth
- KMI 3.97
- CADL N/A
- 52 Week Low
- KMI $21.46
- CADL $3.79
- 52 Week High
- KMI $31.48
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- KMI 60.39
- CADL 38.14
- Support Level
- KMI $27.07
- CADL $4.60
- Resistance Level
- KMI $27.81
- CADL $5.03
- Average True Range (ATR)
- KMI 0.45
- CADL 0.27
- MACD
- KMI 0.12
- CADL -0.02
- Stochastic Oscillator
- KMI 87.66
- CADL 23.50
About KMI Kinder Morgan Inc.
Kinder Morgan is one of the largest midstream energy firms in the US, with an interest in or an operator on more than 80,000 miles of gas, refined products, and carbon dioxide pipelines. The company also owns one of the largest portfolios of gas and refined products storage and terminals. Most of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.